

Discussion on Advances in the Management of Platinum-Resistant Ovarian Cancer

Jie Yang, MD

Peking Union Medical College Hospital

Gynecologic Oncology Division

1. How can we establish standardized biomarker testing frameworks at diagnosis that dynamically incorporate emerging targets beyond BRCA/HRD while addressing spatial/temporal heterogeneity?
2. How to optimize therapeutic timing?
3. How to evaluate and establish better sequencing strategies when integrating novel targeted agents (ADCs, CPI, immunotherapy, pathway inhibitors) ? Transition to frontline therapy?